Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company
Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to a tax-free, all-stock merger of equals creating a CNS-focused company. Pro forma annual revenue is about $2.2B, adjusted EBITDA $888M, with $125M annual cost synergies. Supernus Inc. will trade on Nasdaq as SUPN, with closure expected Q4 2026. Indivior shareholders receive a $1B special cash dividend funded via a $650M Citibank term loan.
How this was made
The 30-second read
Why it matters
The transaction creates a CNS-focused company with specified pro forma revenue, EBITDA, net debt, and cost synergies, plus a pre-close $1 billion special cash dividend to Indivior shareholders financed via a term loan and existing cash.
Market read
Definitive merger terms, dividend mechanics, and the expected Nasdaq listing for the combined entity are immediate catalysts for deal-arb and event-driven positioning.
What to watch
Key execution risks include achieving the stated cost synergies, maintaining growth into the 2030s, and navigating regulatory and shareholder approval hurdles that can delay or alter deal economics.
Background
Supernus Pharmaceuticals and Indivior Pharmaceuticals entered a definitive agreement to combine in a tax-free, all-stock merger of equals.
Ticker impact
Supernus and Indivior agreed to a tax-free all-stock merger, with the combined company named Supernus Inc. trading on Nasdaq as SUPN.
Likely positive near-term sentiment on deal announcement, followed by volatility around regulatory and shareholder approval milestones.
The article discloses definitive merger structure, exchange listing plan, and dividend financing, which typically drives immediate repricing and ongoing event-driven trading.
Market effects
CNS-focused biopharma consolidation could shift competitive dynamics in psychiatry, neurology, and addiction portfolios.
US-listed biotech M&A sentiment may improve for CNS peers, but impact is likely company-specific.
Limited direct global macro linkage, but cross-border investors may reprice CNS M&A risk appetite.
Counterpoint
The $1 billion special dividend funded partly by a $650 million term loan may increase financial risk and reduce flexibility if integration or product growth underperforms.
Key entities
- companySupernus Pharmaceuticals
US CNS biopharma partner in the definitive merger agreement.
- companyIndivior Pharmaceuticals
US CNS biopharma partner; its shareholders receive a $1 billion special cash dividend before closing.
- financial_institutionCitibank
Provided a $650 million term loan commitment to help fund the special dividend.
- companySupernus Inc.
Name of the combined company, expected to trade on Nasdaq under ticker SUPN.
